Clinical trials: Influenza, Human, open to volunteers
Influenza, Human
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
The goal of this Phase II/III study is to investigate the safty and efficacy of 102D-6 in adolescents and adults with influenza. The main aim to answer: 1.
- Trial name
- NCT07893847
- Testing
- 20 mg 102D-6 dry suspension, 40 mg 102D-6 dry suspension
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Capital Medical University
Influenza
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
This study consists of two parts: Part A Surveillance and Part B Transmission. The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' <12…
- Trial name
- Pebblestone (NCT06094010)
- Testing
- Baloxavir Marboxil
- Where
- 51 sites in United States, Bulgaria and 2 more
- Volunteers
- 1,100 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- ANCHOR (NCT07159763)
- Testing
- MK-1406
- Where
- 181 sites in United States, Argentina and 3 more
- Volunteers
- 10,000 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Seasonal Influenza
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
- Trial name
- NCT07870330
- Testing
- mRNA-1010, Fluarix Trivalent
- Where
- 6 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza -Like Illness, Influenza (Healthy Volunteers)
Mucosal and Systemic Immunity Correlates of Protection Against Influenza in Young Children, Aged 2-5 Years (MUSIC-Flu)
Title: Mucosal and systemic immunity correlates of protection against influenza in young children (MUSIC-Flu). The goal of this observational study is to better understand how immune responses in the blood and mucosa are linked…
- Trial name
- MUSIC-Flu (NCT07861854)
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute for Communicable Diseases, South Africa
Immunization; Infection, Transplantation Infection
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV).
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Trial name
- PSOT (NCT05947071)
- Testing
- Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- 10 sites in United States
- Volunteers
- 312 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Sepsis
Immune Responses to Dengue and Sepsis
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza…
- Conditions
- Dengue, Sepsis, Influenza
- Trial name
- DEN-SEP (NCT07040202)
- Where
- 4 sites in Cambodia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Influenza Vaccination
SAVE: School Ambassadors for Vaccine Education
Influenza is associated with millions of cases of school absenteeism due to illness, hundreds of hospitalizations and thousands of deaths in the U.S. each year, which can be greatly reduced with influenza vaccination.
- Trial name
- NCT07164144
- Testing
- Vaccine Communication Training
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza, COVID-19
Respiratory Virus Sampling and Repository
Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections.
- Trial name
- NCT05266222
- Where
- 2 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Upper Resp Tract Infection
Climate Change Trends and Their Impact on the Seasonal Upper Respiratory Tract Disease Burden
Investigators assume that global climate changes can influence upper respiratory tract infection peak prevalence, which may have significant clinical implication, for example, by adjusting seasonal Influenzas' vaccine timing.
- Trial name
- NCT07767019
- Testing
- No Intervention: Observational Cohort
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- Barzilai Medical Center
Respiratory Tract Infections (RTI), Influenza -Like Illness
Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France
Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs).
- Conditions
- Respiratory Tract Infections (RTI), Influenza -Like Illness, Influenza, COVID - 19
- Trial name
- RS-viro IRA (NCT07599449)
- Testing
- saliva sampling, Nasopharyngeal swab
- Where
- France
- Volunteers
- 25,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza (Healthy Volunteers)
SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial)
The flu is a health risk for Canadians. It causes up to 15,000 hospitalizations every year and is one of the top 10 causes of death. Getting a flu vaccine is the best way to prevent the flu and any severe complications.
- Trial name
- SAFE (NCT07739719)
- Testing
- LAIV FLUMIST
- Where
- Canada
- Volunteers
- 966 people, healthy volunteers welcome
- Sponsor
- McMaster University
Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a…
- Trial name
- NCT04712539
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Influenza
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.
This randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Onradivir Tablets in participants aged 12 to 17 years with influenza A virus infection.
- Trial name
- NCT07229547
- Testing
- Onradivir tablet
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Influenza
A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine
Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination
- Trial name
- NCT07545564
- Testing
- LAIV
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
This study plans to learn more about whether a stakeholder-informed, standardized inpatient vaccination program will increase influenza vaccination rates of hospitalized children across US pediatric health systems.
- Trial name
- Influential (NCT05832307)
- Testing
- Existing Influenza Vaccination Practices, Standardized inpatient influenza vaccination program
- Where
- 2 sites in United States
- Volunteers
- 22,000 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
COVID19, Influenza Vaccination
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares…
- Conditions
- COVID19, Influenza Vaccination, ACE Inhibitors, ARB
- Trial name
- NCT04367883
- Testing
- Antihistamine, Amantadine, ACEI
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Consorci Sanitari de Terrassa
Influenza
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room…
- Trial name
- NCT07236814
- Testing
- Suraxavir marboxil, Oseltamivir
- Where
- 2 sites in China
- Volunteers
- 384 people
- Sponsor
- Capital Medical University